CN103772373B - 作为受体酪氨酸激酶抑制剂的喹唑啉类似物 - Google Patents

作为受体酪氨酸激酶抑制剂的喹唑啉类似物 Download PDF

Info

Publication number
CN103772373B
CN103772373B CN201310581100.3A CN201310581100A CN103772373B CN 103772373 B CN103772373 B CN 103772373B CN 201310581100 A CN201310581100 A CN 201310581100A CN 103772373 B CN103772373 B CN 103772373B
Authority
CN
China
Prior art keywords
alkyl
bases
quinazoline
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN201310581100.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103772373A (zh
Inventor
埃利·华莱士
乔治·托帕洛夫
约瑟夫·雷西卡托斯
亚历山大·巴克梅尔特
赵千
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/642,440 external-priority patent/US7501427B2/en
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CN103772373A publication Critical patent/CN103772373A/zh
Application granted granted Critical
Publication of CN103772373B publication Critical patent/CN103772373B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201310581100.3A 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物 Expired - Lifetime CN103772373B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/642,440 2003-08-14
US10/642,440 US7501427B2 (en) 2003-08-14 2003-08-14 Quinazoline analogs as receptor tyrosine kinase inhibitors
US55171804P 2004-03-10 2004-03-10
US60/551,718 2004-03-10
CNA2004800264589A CN1852714A (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800264589A Division CN1852714A (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物

Publications (2)

Publication Number Publication Date
CN103772373A CN103772373A (zh) 2014-05-07
CN103772373B true CN103772373B (zh) 2017-06-09

Family

ID=34198338

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201310428856.4A Expired - Lifetime CN103664802B (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
CN201110283526.1A Expired - Lifetime CN102432552B (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
CN201310581100.3A Expired - Lifetime CN103772373B (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201310428856.4A Expired - Lifetime CN103664802B (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
CN201110283526.1A Expired - Lifetime CN102432552B (zh) 2003-08-14 2004-08-10 作为受体酪氨酸激酶抑制剂的喹唑啉类似物

Country Status (23)

Country Link
US (2) US7452895B2 (enExample)
EP (1) EP1660090B1 (enExample)
JP (1) JP4828421B2 (enExample)
KR (2) KR100953246B1 (enExample)
CN (3) CN103664802B (enExample)
AR (1) AR045378A1 (enExample)
AU (1) AU2004264937B2 (enExample)
BR (1) BRPI0413565B8 (enExample)
CA (1) CA2535614C (enExample)
CL (1) CL2004002066A1 (enExample)
CY (1) CY1113992T1 (enExample)
DK (1) DK1660090T3 (enExample)
ES (1) ES2399427T3 (enExample)
IL (1) IL173593A (enExample)
IS (1) IS8288A (enExample)
MX (1) MXPA06001767A (enExample)
NO (1) NO336275B1 (enExample)
NZ (1) NZ545459A (enExample)
PL (1) PL1660090T3 (enExample)
PT (1) PT1660090E (enExample)
RU (1) RU2350605C2 (enExample)
TW (1) TWI353982B (enExample)
WO (1) WO2005016346A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
KR100953246B1 (ko) 2003-08-14 2010-04-16 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
DE602006009968D1 (de) 2005-11-15 2009-12-03 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
KR102061917B1 (ko) 2011-10-14 2020-01-02 어레이 바이오파마 인크. 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물
AU2012322039C1 (en) 2011-10-14 2021-04-29 Array Biopharma Inc. Solid dispersions of a Erb2 (HER2) inhibitor
SI2827900T1 (en) 2012-03-23 2018-06-29 Array Biopharma, Inc. Amorphous solid dispersion for use in the treatment of brain cancer
WO2017037298A1 (en) * 2015-09-04 2017-03-09 Aslan Pharmaceuticals Pte Limited A combination therapy comprising varlitinib and an anticancer agent
JP2019514864A (ja) * 2016-04-21 2019-06-06 アスラン ファーマシューティカルズ ピーティーイー リミテッド 肝癌の治療方法
GB201611580D0 (en) * 2016-07-01 2016-08-17 Aslan Pharmaceuticals Pte Ltd Method
CN106349230A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN106349231A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一类含卤代噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN106279135A (zh) * 2016-08-09 2017-01-04 浙江医药高等专科学校 一种噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN106317039A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 一种含噻吩磺酰胺结构的乙氧苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106317040A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 含噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
WO2018038684A1 (en) 2016-08-26 2018-03-01 Agency For Science, Technology And Research Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
WO2018160138A1 (en) 2017-03-02 2018-09-07 Aslan Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
JP7328151B2 (ja) 2017-04-28 2023-08-16 シージェン インコーポレイテッド Ｈｅｒ２陽性がんの処置
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
HUE069764T2 (hu) 2018-09-18 2025-04-28 Hoffmann La Roche Kinazolin-származékok, mint daganatellenes szerek
WO2020076239A1 (en) 2018-10-09 2020-04-16 Aslan Pharmaceuticals Pte Ltd Malonate salt of varlitinib
CN111499622B (zh) * 2019-07-08 2023-06-06 山东省科学院菏泽分院 一种治疗胆管癌的药物的制备方法
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
KR20240027048A (ko) 2021-06-26 2024-02-29 어레이 바이오파마 인크. Her2 돌연변이 억제제
WO2023081637A1 (en) * 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
WO2023185793A1 (zh) * 2022-03-28 2023-10-05 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
WO2025067396A1 (zh) * 2023-09-27 2025-04-03 江苏恒瑞医药股份有限公司 一种喹唑啉衍生物的可药用盐、其结晶形式及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1211240A (zh) * 1996-02-14 1999-03-17 曾尼卡有限公司 作为抗肿瘤剂的喹唑啉衍生物
WO2001098277A2 (en) * 2000-06-22 2001-12-27 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583774A (en) 1948-04-30 1952-01-29 Merck & Co Inc Vitamin b6 derivatives
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5204348A (en) 1988-10-06 1993-04-20 Mitsui Toatsu Chemicals Inc. Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (enExample) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
EP1110953B1 (en) * 1995-03-30 2009-10-28 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
RO121900B1 (ro) 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
JP2001522853A (ja) 1997-11-11 2001-11-20 ファイザー・プロダクツ・インク 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体
EP1066039A4 (en) 1998-03-02 2003-02-26 Cocensys Inc SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES
US6017922A (en) 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
EP1131304B1 (en) 1998-11-19 2002-12-04 Warner-Lambert Company N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
YU49401A (sh) 1999-01-13 2004-07-15 Warner-Lambert Company Benzoheterocikli i njihova upotreba kao inhibitori mek
TR200500745T2 (tr) * 1999-02-10 2005-05-23 Astrazeneca Ab Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
HUP0204413A3 (en) 1999-09-21 2003-07-28 Astrazeneca Ab Quinazoline compounds, their preparation, their use and pharmaceutical compositions containing them
ATE295348T1 (de) 2000-02-17 2005-05-15 Bristol Myers Squibb Co Thyroid-rezeptorliganden, die von anilin ableitbar sind
MXPA02012034A (es) 2000-06-06 2003-04-25 Pfizer Prod Inc Derivados de tiofeno utiles como agentes anticancerosos.
CZ300945B6 (cs) 2000-06-30 2009-09-23 Glaxo Group Limited Zpusob prípravy 5-(6-chinazolinyl)-furan-2-karbaldehydu
WO2003015778A1 (en) 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003037252A2 (en) 2001-10-30 2003-05-08 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE423104T1 (de) * 2001-11-03 2009-03-15 Astrazeneca Ab Quinazolin derivate als antitumor-mittel
ES2333702T3 (es) * 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
KR20050122199A (ko) 2003-01-23 2005-12-28 티.케이. 시그널 리미티드 표피성장인자 수용체 티로신 키나제의 비가역성 억제제 및 그의 용도
PE20040945A1 (es) 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
JP2007501854A (ja) 2003-05-27 2007-02-01 ファイザー・プロダクツ・インク 受容体型チロシンキナーゼ阻害薬としてのキナゾリン類およびピリド［３，４−ｄ］ピリミジン類
KR100953246B1 (ko) 2003-08-14 2010-04-16 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
SG135193A1 (en) 2003-08-18 2007-09-28 Pfizer Prod Inc Dosing schedule for erbb2 anticancer agents
WO2005044302A1 (en) 2003-11-06 2005-05-19 Pfizer Products Inc. Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
DE602006009968D1 (de) 2005-11-15 2009-12-03 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1211240A (zh) * 1996-02-14 1999-03-17 曾尼卡有限公司 作为抗肿瘤剂的喹唑啉衍生物
WO2001098277A2 (en) * 2000-06-22 2001-12-27 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A mild cyclodesulfurization of N-(2-hydroxyethyl)-N’-phenylthioureas to 2-phenylamino-2-oxazolines using TsCl/NaOH;Taek Hyeon Kim,等;《Tetrahedron》;20011231;第57卷;7137-7141 *
A Selective and Convenient Method for the Synthesis of 2-Phenylaminothiazolines;April L. Bernacki，等;《Organic Letters》;20101101;第12卷(第23期);5526-5529 *
Synthesis of N-benzothiazol-2-yl-amides by a copper-catalyzed intramolecular cyclization process;Junke Wang，等;《Tetrahedron Letters》;20071122;第49卷;467-470 *

Also Published As

Publication number Publication date
ES2399427T3 (es) 2013-04-01
AU2004264937A1 (en) 2005-02-24
BRPI0413565B1 (pt) 2019-10-01
US7452895B2 (en) 2008-11-18
JP4828421B2 (ja) 2011-11-30
TWI353982B (en) 2011-12-11
CA2535614A1 (en) 2005-02-24
KR101028952B1 (ko) 2011-04-12
US8278314B2 (en) 2012-10-02
US20050043334A1 (en) 2005-02-24
NO336275B1 (no) 2015-07-06
RU2350605C2 (ru) 2009-03-27
IL173593A (en) 2011-11-30
CY1113992T1 (el) 2016-07-27
CL2004002066A1 (es) 2005-06-03
EP1660090A4 (en) 2008-12-03
IS8288A (is) 2006-02-07
US20090048279A1 (en) 2009-02-19
AR045378A1 (es) 2005-10-26
PT1660090E (pt) 2013-01-11
HK1085400A1 (en) 2006-08-25
IL173593A0 (en) 2006-07-05
EP1660090A1 (en) 2006-05-31
MXPA06001767A (es) 2006-05-12
CN103664802B (zh) 2015-08-05
CN102432552A (zh) 2012-05-02
BRPI0413565A (pt) 2006-10-17
RU2006103493A (ru) 2007-09-20
CA2535614C (en) 2009-12-22
CN102432552B (zh) 2016-01-20
NO20061171L (no) 2006-04-10
DK1660090T3 (da) 2012-12-17
KR20100018079A (ko) 2010-02-16
TW200519096A (en) 2005-06-16
KR20060064630A (ko) 2006-06-13
JP2007502295A (ja) 2007-02-08
AU2004264937B2 (en) 2010-04-29
CN103772373A (zh) 2014-05-07
KR100953246B1 (ko) 2010-04-16
PL1660090T3 (pl) 2013-04-30
CN103664802A (zh) 2014-03-26
EP1660090B1 (en) 2012-11-21
BRPI0413565B8 (pt) 2021-05-25
WO2005016346A1 (en) 2005-02-24
NZ545459A (en) 2009-12-24

Similar Documents

Publication Publication Date Title
CN103772373B (zh) 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
CN101687822B (zh) 二(芳基氨基)芳基化合物
AU664496B2 (en) Quinazoline derivatives
ES2457396T3 (es) 3-Cianoquinolinas sustituidas como inhibidores de las proteínas tirosina quinasas
JP7337951B2 (ja) 癌を治療するための窒素含有芳香族ヘテロ環アミド誘導体
CN100412066C (zh) 用作蛋白激酶抑制剂的化合物和组合物
AU2021326209B2 (en) EFGR inhibitor, preparation method therefor, and application thereof
CN115057855B (zh) 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
SK284846B6 (sk) Deriváty substituovaného 3-kyanochinolínu, spôsob ich prípravy, ich použitie a farmaceutický prostriedok s ich obsahom
EP1178966B1 (en) Quinoline derivatives as inhibitors of mek enzymes
CN102348708A (zh) 激酶抑制剂的前药形式及其在治疗中的用途
KR20170031241A (ko) 시클린-의존성 키나제 (cdk) 억제제로서의 2-h-인다졸 유도체 및 그의 치료적 용도
JP2015524448A (ja) アルキニルへテロ芳香環化合物及びその応用
CN107074874A (zh) Erk抑制剂
EP1814545A2 (en) Compounds and compositions as protein kinase inhibitors
CN105315285A (zh) 2,4-二取代7H-吡咯并[2,3-d]嘧啶衍生物、其制法与医药上的用途
JP2019536766A (ja) ２−置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途
CN102875570A (zh) 喹唑啉衍生物及其制备方法和用途
CN108047205B (zh) 2-(2，4，5-取代苯氨基)嘧啶衍生物、其制备方法及其在制备抗肿瘤药物中的应用
CN102812010B (zh) 喹唑啉衍生物及其制备方法和应用
CN115746023B (zh) 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法
ZA200601333B (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
TW201738227A (zh) 一種稠環化合物、其製備方法和應用及其中間體化合物
JP2025526715A (ja) ピリジノピリミジノン化合物の結晶、その酸塩、その酸塩の結晶及び使用
KR20250041906A (ko) Hpk1 및 mlk3 저해 활성을 갖는 신규한 화합물 및 이를 함유하는 항암용 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20170609

CX01 Expiry of patent term